Ocugen Advances Gene Therapy Programs for Retinal Diseases with Phase 3 Trials on March 25, 2026 Blindness dry AMD gene therapy Geographic Atrophy OCU400 OCU410 Ocugen Phase 3 Retinitis Pigmentosa +
Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3 on December 15, 2025 avacincaptad AVD-104 clinical trial failure Clinical Trials dry AMD Genus Aviceda Geographic Atrophy Izervay pegol Phase 3 prospects Sialic Acid Binding Immunoglobulin-like Lectins +